Agenus (AGEN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$132.7M

Revenue (quarter)

$34.5M

Revenue growth (year over year)

+34.36%

Gross profit (trailing twelve months)

$132.1M

Gross margin

99.52%

Net income (trailing twelve months)

$91.9M

Net income (quarter)

−$567,000.00

Net income growth (year over year)

+98.11%

Net margin

69.29%

Return on equity

—

EPS (trailing twelve months)

$3.00

Book value per share

−$4.67

P/E (trailing twelve months)

3.20

Price to book

—

Debt to assets

219.20%

Payout ratio

—

Dividend yield

—

Company profile

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

• Is Agenus (AGEN) profitable?

  Yes. Agenus earned $91.9M in net income over the trailing twelve months, a net margin of 69.29%.

• How much revenue does Agenus (AGEN) make?

  Agenus generated $132.7M in revenue over the trailing twelve months, up 34.36% year over year.

• What is AGEN's P/E ratio?

  Agenus trades at 3.2 times trailing twelve-month earnings, on an EPS of $3.00.

• How do I buy stock in Agenus (AGEN)?

  AGEN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.